Organization
The Tisch Cancer Institute
8 abstracts
Abstract
Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.Org: Stephenson Cancer Center, The Tisch Cancer Institute, Mayo Clinic Cancer Center Scottsdale, The University of Arizona Cancer Center, City of Hope Comprehensive Cancer Center,
Abstract
C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Hospital, Mount Sinai Beth Israel, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Clinical validity of TTMV-HPV DNA liquid biopsies for the diagnosis and surveillance of HPV-associated oropharyngeal carcinoma.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Icahn School of Medicine Department of Pathology, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, The Tisch Cancer Institute,
Abstract
The incidence of thyroid-related adverse events in solid tumors receiving immune checkpoint blockade with curative intent: A meta-analysis.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Beth Israel, Yokohama City University Hospital, The Tisch Cancer Institute,
Abstract
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).Org: Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York-Presbyterian Hospital, The Tisch Cancer Institute,
Abstract
Nominating molecular/immunologic drivers of central nervous system (CNS) metastases in squamous cell carcinoma of the head/neck (SCCHN).Org: Pritzker School of Medicine, The University of Chicago Medicine Center for Advanced Care at Orland Park, MD Anderson Hematology/Oncology Fellowship, Canter for Head and Neck Oncology, Dana-Farber Cancer Institute,
Abstract
Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab.Org: Geneos Therapeutics, Plymouth Meeting, PA, Personalis, Inc., Menlo Park, CA, University of Auckland,
Abstract
C-reactive protein (CRP) as a prognostic biomarker in patients with bladder cancer: A meta-analysis.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Beth Israel, Mount Sinai Hospital, The Tisch Cancer Institute,